-
平臺編號：bio-68766
-
國際編號：CRL-2544?
-
細(xì)胞信息： SaI/N
-
規(guī)格：frozen
-
用途：ATCC原裝細(xì)胞
-
服務(wù)費(fèi)用：
加載中…… - 訂購
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫為準(zhǔn)）
SaI/N
細(xì)胞類型：其他細(xì)胞類型
是否是腫瘤細(xì)胞：0
物種來源：小鼠
生長狀態(tài)：貼壁生長
ATCC Number：CRL-2544?
相關(guān)疾?。浩渌膊?br /> 運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
細(xì)胞形態(tài)：成纖維樣
規(guī)格：0.5ml Designations: SaI/N
Depositors: ?S Ostrand-Rosenberg
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Mus musculus deposited as mouse
Morphology:fibroblast
Source: Disease: fibrosarcoma, malignant
Cell Type: dibenzanthracene induced
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Antigen Expression:H-2a
MHC class I +; MHC class II - [49807 ]
Comments:The Sarcoma I tumor originated in 1947 in a mouse that had been treated with dibenzanthracene
The SaI variant (ATCC CRL-2543 ) grows as an ascites tumor when inoculated intraperitoneally, while the SaI/N variant grows as a solid tumor when inoculated subcutaneously [49807 ]
The cell line can be used as a model for testing immunotherapy protocols. It can be used in immunology and cancer studies. The cells may be used for transfection studies.
A culture submitted to the ATCC in October of 2000 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline.
The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Growth Conditions: NOTE: the cells should not be allowed to become confluent, subculture at 80 to 90% of confluence.
Subculturing: Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
References: 49807: Baskar S, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619-629, 1995. PubMed: 7836917
是否是腫瘤細(xì)胞：0
物種來源：小鼠
生長狀態(tài)：貼壁生長
ATCC Number：CRL-2544?
相關(guān)疾?。浩渌膊?br /> 運(yùn)輸方式：凍存運(yùn)輸
數(shù)量：大量
細(xì)胞形態(tài)：成纖維樣
規(guī)格：0.5ml Designations: SaI/N
Depositors: ?S Ostrand-Rosenberg
Biosafety Level:1
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Mus musculus deposited as mouse
Morphology:fibroblast
Source: Disease: fibrosarcoma, malignant
Cell Type: dibenzanthracene induced
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic:Yes
Antigen Expression:H-2a
MHC class I +; MHC class II - [49807 ]
Comments:The Sarcoma I tumor originated in 1947 in a mouse that had been treated with dibenzanthracene
The SaI variant (ATCC CRL-2543 ) grows as an ascites tumor when inoculated intraperitoneally, while the SaI/N variant grows as a solid tumor when inoculated subcutaneously [49807 ]
The cell line can be used as a model for testing immunotherapy protocols. It can be used in immunology and cancer studies. The cells may be used for transfection studies.
A culture submitted to the ATCC in October of 2000 was found to be contaminated with mycoplasma. Progeny were cured by a 21-day treatment with BM Cycline.
The cells were assayed for mycoplasma, by the Hoechst stain, PCR and the standard culture test, after a six-week period following treatment. All tests were negative.
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Growth Conditions: NOTE: the cells should not be allowed to become confluent, subculture at 80 to 90% of confluence.
Subculturing: Protocol:
- Remove and discard culture medium.
- Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
-
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal. - Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
- Add appropriate aliquots of the cell suspension to new culture vessels.
- Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products:Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2005
recommended serum:ATCC 30-2020
References: 49807: Baskar S, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619-629, 1995. PubMed: 7836917
